

MTN 026 - Dapivirine Gel Rectal Safety and PK Study
Report Generation Date: December 2, 2025
Visit Cutoff Date: January 26, 2019¹
Retention by Visit and Site

	All Sites	Birmingham, AL	Pittsburgh, PA	Bangkok, Thailand
Participants Enrolled	28	9	10	9
Visit 3: Day 7 Single Dose Visit				
Expected ²	27	8	10	9
Completed ³	25 (93%)	8 (100%)	10 (100%)	7 (78%)
Not Completed	2 (7%)	0 (0%)	0 (0%)	2 (22%)
Missed	2 (7%)	0 (0%)	0 (0%)	2 (22%)
Terminated Early	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Not Expected	0	0	0	0
Visit 4: Day 8 Sampling Visit				
Expected ²	27	8	10	9
Completed ³	26 (96%)	8 (100%)	9 (90%)	9 (100%)
Not Completed	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Missed	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Terminated Early	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Not Expected	0	0	0	0
Visit 5: Day 9 Sampling Visit				
Expected ²	27	8	10	9
Completed ³	26 (96%)	8 (100%)	9 (90%)	9 (100%)
Not Completed	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Missed	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Terminated Early	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Not Expected	0	0	0	0

¹ This report includes data received at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received at SCHARP.

MTN 026 - Dapivirine Gel Rectal Safety and PK Study
Report Generation Date: December 2, 2025
Visit Cutoff Date: January 26, 2019¹
Retention by Visit and Site

	All Sites	Birmingham, AL	Pittsburgh, PA	Bangkok, Thailand
Visit 6: Day 10 Sampling Visit				
Expected ²	27	8	10	9
Completed ³	26 (96%)	8 (100%)	9 (90%)	9 (100%)
Not Completed	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Missed	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Terminated Early	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Not Expected	0	0	0	0
Visit 7: Day 24 Study Product Visit				
Expected ²	27	8	10	9
Completed ³	25 (93%)	8 (100%)	9 (90%)	8 (89%)
Not Completed	2 (7%)	0 (0%)	1 (10%)	1 (11%)
Missed	1 (4%)	0 (0%)	0 (0%)	1 (11%)
Terminated Early	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Not Expected	0	0	0	0
Visit 8: Day 25 Study Product Visit				
Expected ²	27	8	10	9
Completed ³	26 (96%)	8 (100%)	9 (90%)	9 (100%)
Not Completed	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Missed	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Terminated Early	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Not Expected	0	0	0	0

¹ This report includes data received at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received at SCHARP.

MTN 026 - Dapivirine Gel Rectal Safety and PK Study
Report Generation Date: December 2, 2025
Visit Cutoff Date: January 26, 2019¹
Retention by Visit and Site

	All Sites	Birmingham, AL	Pittsburgh, PA	Bangkok, Thailand
Visit 9: Day 26 Study Product Visit				
Expected ²	27	8	10	9
Completed ³	25 (93%)	8 (100%)	8 (80%)	9 (100%)
Not Completed	2 (7%)	0 (0%)	2 (20%)	0 (0%)
Missed	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Terminated Early	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Not Expected	0	0	0	0
Visit 10: Day 27 Study Product Visit				
Expected ²	27	8	10	9
Completed ³	25 (93%)	8 (100%)	8 (80%)	9 (100%)
Not Completed	2 (7%)	0 (0%)	2 (20%)	0 (0%)
Missed	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Terminated Early	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Not Expected	0	0	0	0
Visit 11: Day 28 Study Product Visit				
Expected ²	27	8	10	9
Completed ³	25 (93%)	8 (100%)	8 (80%)	9 (100%)
Not Completed	2 (7%)	0 (0%)	2 (20%)	0 (0%)
Missed	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Terminated Early	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Not Expected	0	0	0	0

¹ This report includes data received at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received at SCHARP.

MTN 026 - Dapivirine Gel Rectal Safety and PK Study
Report Generation Date: December 2, 2025
Visit Cutoff Date: January 26, 2019¹
Retention by Visit and Site

	All Sites	Birmingham, AI	Pittsburgh, PA	Bangkok, Thailand
Visit 12: Day 29 Study Product Visit				
Expected ²	27	8	10	9
Completed ³	25 (93%)	8 (100%)	8 (80%)	9 (100%)
Not Completed	2 (7%)	0 (0%)	2 (20%)	0 (0%)
Missed	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Terminated Early	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Not Expected	0	0	0	0
Visit 13: Last Study Product Visit				
Expected ²	27	8	10	9
Completed ³	25 (93%)	8 (100%)	8 (80%)	9 (100%)
Not Completed	2 (7%)	0 (0%)	2 (20%)	0 (0%)
Missed	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Terminated Early	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Not Expected	0	0	0	0
Visit 14: Day 31 Sampling Visit				
Expected ²	27	8	10	9
Completed ³	25 (93%)	8 (100%)	8 (80%)	9 (100%)
Not Completed	2 (7%)	0 (0%)	2 (20%)	0 (0%)
Missed	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Terminated Early	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Not Expected	0	0	0	0

¹ This report includes data received at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received at SCHARP.

MTN 026 - Dapivirine Gel Rectal Safety and PK Study
Report Generation Date: December 2, 2025
Visit Cutoff Date: January 26, 2019¹
Retention by Visit and Site

	All Sites	Birmingham, AI	Pittsburgh, PA	Bangkok, Thailand
Visit 15: Day 32 Sampling Visit				
Expected ²	27	8	10	9
Completed ³	25 (93%)	8 (100%)	8 (80%)	9 (100%)
Not Completed	2 (7%)	0 (0%)	2 (20%)	0 (0%)
Missed	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Terminated Early	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Not Expected	0	0	0	0
Visit 16: Day 33 Sampling Visit				
Expected ²	27	8	10	9
Completed ³	25 (93%)	8 (100%)	8 (80%)	9 (100%)
Not Completed	2 (7%)	0 (0%)	2 (20%)	0 (0%)
Missed	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Terminated Early	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Not Expected	0	0	0	0
Visit 17: Termination Visit				
Expected ²	27	8	10	9
Completed ³	25 (93%)	8 (100%)	8 (80%)	9 (100%)
Not Completed	2 (7%)	0 (0%)	2 (20%)	0 (0%)
Missed	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Terminated Early	1 (4%)	0 (0%)	1 (10%)	0 (0%)
Not Expected	0	0	0	0

¹ This report includes data received at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received at SCHARP.